✦ LIBER ✦

299 POSTER Randomized phase II trial of irofulven/prednisone, irofulven/capecitabine/prednisone, or mitoxantrone/prednisone in hormone refractory prostate cancer (HRPC) patients failing first-line docetaxel: preliminary results

✍ Scribed by L. Hart; J. Hainsworth; T. Ciuleanu; S. Oudard; E. Berger; J. Alexandre; K. Chi; D. Ruether; C. Kahatt; J. MacDonald

Book ID: 118623927
Publisher: Elsevier Science
Year: 2006
Tongue: English
Weight: 59 KB
Volume: 4
Category: Article
ISSN: 1359-6349
DOI: 10.1016/s1359-6349(06)70304-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II randomised trial of docetaxel (

Phase II randomised trial of docetaxel (D), estramustine (E) and prednisone (P) — Two schedules — versus mitoxantrone (M) and prednisone in patients (PTS) with hormone refractory prostate cancer (HRPC)

✍ S. Qudard; E.B. Banu; E. Voog; H. Hardy-Bessard; C. Linassier; P. Beuzeuboe; A. 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 187 KB

Activity of second-line chemotherapy in

Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : Randomized phase 2 study of ixabepilone or mitoxantrone and prednisone

✍ Jonathan E. Rosenberg; Vivian K. Weinberg; W. Kevin Kelly; Dror Michaelson; Maha 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 147 KB 👁 1 views

## Abstract ## BACKGROUND. This randomized, noncomparative, multicenter, clinical trial evaluated ixabepilone or mitoxantrone/prednisone (MP) as second‐line chemotherapy for taxane‐refractory, hormone‐refractory, prostate cancer (HRPC). ## METHODS. Patients with HRPC that progressed during or wi

211 POSTER Results of a phase II study o

211 POSTER Results of a phase II study of picoplatin with docetaxel and prednisone in chemotherapy-naive patients with metastatic hormone refractory prostate cancer (HRPC)

✍ R. DeJager; L. Roman; N. Lopatkin; P. Karlov; H.B. Breitz; R. Earhart 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 59 KB